The news was mostly good for Boston-area life sciences firms this past week, with some money raised, some deals done, and some intriguing new technologies unveiled.
—Luke talked to Tod Woolf, CEO of RXi Pharmaceuticals (NASDAQ: [[ticker:RXII]]), about the tremendous challenge of delivering RNAi-based drugs—and how the Worcester, MA-based firm plans to overcome it. Its goal: an oral pill that uses RNA interference to combat inflammatory diseases like rheumatoid arthritis, asthma, Crohn’s disease, psoriasis, atherosclerosis, and Type 2 diabetes.
—New England Patriots owner the Kraft Group is reportedly looking for tenants for a 1.6-million-square-foot biotech office park it’s planning to build near Foxborough’s Gillette Stadium.
—Pharmaceutical behemoth Pfizer (NYSE:[[ticker:PFE]]) unveiled plans for an independent research unit—located in Cambridge, England, and Cambridge, MA—aimed at developing stem-cell-based treatments for multiple diseases.
—Ascent Therapeutics finally lifted the lid on its technology. Ryan learned that the Cambridge, MA-based biotech is developing a new class of molecules, which it calls “pepducins,” designed to target an important type of molecule on cell surfaces in a new way. The technology intrigued investors enough to help Ascent raise $19 million in a Series A venture capital round from the likes of HealthCare Ventures, Novartis Option Fund, and TVM Capital.
—Cambridge, MA-based ZafGen, which is developing fat-fighting drugs, raised $14 million in a Series B round from Third Rock Ventures and Atlas Venture.
—An FDA panel found in a 10-8 vote that Targanta Therapeutics (NASDAQ:[[ticker:TARG]]) has not yet proved that its experimental antibiotic oritavancin is safe and effective. Though the FDA
